We offer approximately 1,000 molecules covering a broad range of therapeutic areas and are a recognized leader in Antibiotics with over 150 different product and technology combinations.
We have a very high LoE coverage and are on track to submit 40 ‘first to files’ in the US by 2024.
We would be excited to discuss partnerships that allow us to strengthen our footprint in differentiated and/or promotable generics. We would consider all requests, in a therapeutic area agnostic manner, but would be especially interested in opportunities in the anti-infectives and respiratory segments.
Small Molecules
